Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

49.2K
Overview
49.2K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

93
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
93
Cancer Vaccines01:30

Cancer Vaccines

621
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
621
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

102
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
102
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

77
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
77
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

67
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
67

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years.

Open forum infectious diseases·2026
Same author

Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19.

Clinical & translational immunology·2025
Same author

More than half of shoulder vaccinations may end up in the subacromial space.

NPJ vaccines·2025
Same author

Dendritic cells and HIV transmission: roles and subsets of antigen-presenting cells in the human anogenital tract.

PLoS pathogens·2025
Same author

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy.

RMD open·2025
Same author

Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.

EClinicalMedicine·2025

Related Experiment Video

Updated: Nov 16, 2025

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.5K

Vaccines for older adults.

Anthony L Cunningham1, Peter McIntyre2, Kanta Subbarao3

  • 1Centre for Virus Research, The Westmead Institute for Medical Research, Faculty of Medicine and Health, University of Sydney, Australia tony.cunningham@sydney.edu.au.

BMJ (Clinical Research Ed.)
|February 23, 2021
PubMed
Summary

Older adults face increasing infection risks. Recent vaccine advancements for shingles, influenza, and pneumococcal disease offer improved protection and higher efficacy, boosting confidence and uptake in this growing population.

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.0K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.6K

Related Experiment Videos

Last Updated: Nov 16, 2025

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.5K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.0K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.6K

Area of Science:

  • Gerontology and Immunology
  • Vaccinology and Public Health

Background:

  • Global population aging leads to increased susceptibility to infections in individuals aged 65 and older.
  • Vaccine-preventable diseases pose significant morbidity and mortality risks for the elderly, including SARS-CoV-2, influenza, zoster, and pneumococcal infections.

Purpose of the Study:

  • To review advancements in immunization strategies for the three most critical vaccine-preventable diseases affecting older adults.
  • To highlight improvements in vaccine efficacy, immunogenicity, and potential for co-administration to enhance public health outcomes.

Main Methods:

  • Review of current literature on vaccine efficacy and immunogenicity for zoster, influenza, and pneumococcal diseases in older populations.
  • Analysis of vaccine improvement strategies, including novel adjuvants and increased antigen concentration.
  • Examination of factors influencing vaccine effectiveness, durability, and public uptake.

Main Results:

  • Recombinant zoster vaccine demonstrates high efficacy (90%) with sustained protection for over four years, minimally impacted by age.
  • Enhanced influenza vaccines (adjuvanted or higher antigen dose) show improved immunogenicity, though effectiveness and durability require further study.
  • Pneumococcal vaccines (conjugate and polysaccharide) offer similar efficacy against invasive disease and pneumonia; relative value depends on serotype prevalence and prior vaccination coverage.

Conclusions:

  • Significant progress in vaccine development offers enhanced protection for older adults against major infectious diseases.
  • Co-administration of vaccines is feasible and recommended for maximizing uptake and public health benefits.
  • Accelerated development of new vaccine platforms, spurred by SARS-CoV-2, promises future innovations against other pathogens.